Indeed, the treatment restored normal levels of several myelin markers, such as MBP, MAG, and CNP, whose reduction has been reported in different HD settings [6,25], and increased levels of Mog and Plp mRNA expression. The gene discussed is MBP; the disease is Huntington disease.